不活化ワクチンの世界市場：2025年～2033年

世界の不活化ワクチン市場は、2024年に226億米ドルに達し、2033年までには342億6,000万米ドルに達すると予測され、予測期間中の2024年から2032年のCAGRは4.8%で成長する見込みです。

ワクチンは、様々な種類の感染症に対する免疫力を人々に提供する生物学的製品です。ワクチンは、弱毒化、不活化、または病原体の残骸から構成され、投与されると身体の免疫システムを誘発し、抗体の産生を助けます。不活化ワクチンは、死滅した病原体からなるもので、免疫力が長続きしません。不活化ワクチンでは、必要な免疫レベルを得るために、繰り返し投与（ブースター投与）する必要があります。

不活化ワクチンで最もよく治療される病原体感染症は、ポリオ、狂犬病、ジフテリア、破傷風、百日咳、季節性インフルエンザ、A型肝炎、日本脳炎などです。

市場力学：

促進要因と抑制要因

世界の予防接種プログラムの増加

ワクチンは予防ヘルスケアにおいて極めて重要であり、感染症による世界の負担を回避します。ワクチン接種は、ポリオ、ジフテリア、破傷風、百日咳などの致死的感染症から新生児を予防するために、世界中で日常的に行われているヘルスケアです。世界保健機関（WHO）や国連児童基金（ユニセフ）などの世界の保健機関は、これらの感染症の撲滅を目指したワクチン接種プログラムに積極的に取り組んでいます。これらのプログラムは、不活化ワクチンへのアクセスを改善し、市場成長を後押しする不活化ワクチンへの高い需要を生み出すと予測されています。

例えば、世界保健機関は最近、野生ポリオウイルス1型（WPV1）を2027年末までに根絶し、循環型2型変種ポリオウイルス（cVDPV2/ワクチン由来ポリオウイルス）を2029年末までに根絶するため、ポリオ根絶戦略2022-2026を2029年末まで延長しました。このプログラムは世界各国政府から支持され、プログラム延長のために約24億米ドルの資金が提供されました。このプログラム延長の主な成果は、ワクチン接種率の向上であり、メーカーにとっては販売額と販売量の改善につながり、市場成長の原動力にもなっています。

サプライチェーンの不一致は市場成長を抑制する可能性があります。

サプライチェーンの不一致は、ワクチン接種率を低下させ、世界の予防接種プログラムに影響を与え、市場全体を混乱させることにより、不活化ワクチン市場に多大な影響を与える可能性があります。このようなサプライチェーンの不一致は、世界の需要を上回る限定的な生産、限られた製造業者、突発的なアウトブレイクなどによって引き起こされます。例えば、2024年には世界保健機関（WHO）によってコレラの大流行が報告され、26カ国から30万7,433人の患者と2,326人の死者が出ました。不活化コレラワクチンであるデュコラルの需要が高まっており、このワクチン不足は英国を含む様々な国で報告されました。このようにワクチンの供給が限られていることは、より大きな需要を生かす機会を妨げることになりかねません。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 世界中で増加する予防接種プログラム
  • 抑制要因
    • サプライチェーンの不一致
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• 疫学
• 価格分析
• パイプライン分析
• 特許分析
• 規制分析

第6章 病原体別

• 細菌
• ウイルス

第7章 ワクチンタイプ別

• ポリオワクチン
• DTaPワクチン
• インフルエンザワクチン
• 肝炎ワクチン
• 日本脳炎ワクチン
• 狂犬病ワクチン
• コレラワクチン
• その他

第8章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州地域
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋
• 中東・アフリカ

第9章 競合情勢

• 競合シナリオ
• 市況・シェア分析
• M&A分析

第10章 企業プロファイル

• Serum Institute of India Pvt. Ltd.
  • 会社概要
  • 製品ポートフォリオ
    • 製品説明
    • 製品の主要業績評価指標（KPI）
    • 過去および予測の製品販売
    • 製品販売量
  • 財務概要
    • 会社の収益
    • 地域別収益分配
    • 収益予測
  • 主な発展
    • 合併と買収
    • 主な製品開発活動
    • 規制当局の承認等
  • SWOT分析
• GSK plc.
• Sanofi.
• Biological E Limited.
• Bharat Biotech.
• Bio Farma
• Merck & Co., Inc.
• Valneva SE.
• Pfizer Inc.
• KM Biologics
• 各市場参入企業に対しても同様のデータが提供されます。

第11章 付録

The global inactivated vaccines market reached US$ 22.60 billion in 2024 and is expected to reach US$ 34.26 billion by 2033, growing at a CAGR of 4.8% during the forecast period 2024-2032.

Vaccines are biological products that provide immunity to people against various types of infections. Vaccines consist of live-attenuated, inactivated, or remnants of pathogens, which trigger the body's immune system when administered, and aid in the production of antibodies. Inactivated vaccines are those which consist of killed pathogens, and do not provide immunity that lasts long. With inactivated vaccines, repeated doses (booster doses) are necessary to attain the required level of immunity.

The most commonly treated pathogenic infections with inactivated vaccines are polio, rabies, diphtheria, tetanus, pertussis, seasonal influenza, hepatitis A, Japanese encephalitis, etc.

Market Dynamics: Drivers & Restraints

The rising immunization programs across the globe

Vaccines are crucial in preventive healthcare, avoiding the global burden of infectious diseases. Vaccination is a routine healthcare practice worldwide to immunize newborns against deadly infections such as polio, diphtheria, tetanus, and pertussis. Global health organizations such as the World Health Organization (WHO), the United Nations Children's Fund (UNICEF), and others are actively involved in vaccination programs aiming to eradicate these infections. These programs are anticipated to improve access to inactivated vaccines and create a higher demand for them propelling their market growth.

For instance, global health organizations have recently extended the Polio Eradication Strategy 2022-2026 to the end of 2029 to eradicate wild poliovirus type 1 (WPV1) by the end of 2027 and eliminate circulating type 2 variant poliovirus (cVDPV2/ vaccine-derived poliovirus) by the end of 2029. This program was supported by governments across the world and has provided a fund of nearly US$ 2.4 billion for the extended program. The major outcome of this program extension is an improved vaccination rate benefiting the manufacturers to improve their sales value and volume, also driving market growth.

Supply chain discrepancies may restrain the market growth.

Supply chain discrepancies can tremendously impact the market of inactivated vaccines, by reducing vaccine coverage, impacting the global immunization programs, and deflecting the overall market. These supply chain discrepancies are caused by limited production outpaced by global demand, limited manufacturers, sudden outbreaks, etc. For instance, in 2024, a cholera outbreak was reported by the World Health Organization, with 307,433 cases and 2,326 deaths from 26 countries. There is a higher demand for Dukoral, an inactivated cholera vaccine, and this vaccine shortage was reported in various countries including the United Kingdom. This limited supply of vaccines can hinder the opportunity to capitalize on the larger demand.

Segment Analysis

The global inactivated vaccines market is segmented based on pathogen, vaccine type, and region.

Influenza vaccine in the vaccine type segment is dominating the market.

Influenza vaccines also known as flu shots are the ones that protect the recipient against influenza viruses which cause respiratory illnesses. Vaccination is currently the best preventive measure to fight influenza viruses. As per the World Health Organization (WHO), between 3 to 5 million severe influenza cases are reported each year, and 290k to 650k respiratory deaths. The WHO also states that the influenza virus is constantly evolving which requires frequent reformulation of influenza vaccines, and annual immunization. The inactivated influenza vaccines are the most widely used and are categorized as trivalent (3 strains; TIV) and quadrivalent (4 strains; QIV). These vaccines possess excellent safety profiles with minimal side effects and can be prescribed to anyone above 6 months of age, including special populations such as pregnant women.

The market for influenza vaccines is high among all the inactivated vaccines, majorly due to their higher demand during flu season each year, and frequency of administration. The Global Vaccine Report by the WHO states that Influenza vaccines are the ones with high sales value and volume as they are sold in high-income countries where the disease burden is also high.

Geographical Analysis

North America dominated the inactivated vaccines market.

North America region is well known for its advanced healthcare system, public health policies, and immunization programs. The U.S., which is the global leader in the healthcare industry, houses vaccine manufacturers who sell advanced vaccines, meeting the demands of the country. As the U.S. is a high-income country there is a clear disparity in the prices they pay as compared to other nations of the world. Manufacturers tend to generate most of their revenue from the region due to higher vaccine costs, which is a major contributor to the region's dominance.

For instance, influenza vaccine is the dominating one in the inactivated vaccines market. Sanofi is a global leader in the manufacturing and supply of inactivated influenza vaccines. In 2023, the company reported a sale of 2,699 Euro million (2,886 USD million) for influenza vaccines of which ~52% of the sales are from the U.S. market.

The burden of infectious diseases is also high in the region, creating a higher demand for inactivated vaccines. For instance, as per the Centers for Disease Control and Prevention (CDC), in the U.S. nearly 40 million respiratory illnesses, 470k hospitalizations, and 28k deaths resulted from influenza infections in 2023-2024.

All these factors reflect why the North America region, especially the U.S. dominates the global inactivated vaccines market.

Competitive Landscape

The major global players in the inactivated vaccines market are Serum Institute of India Pvt. Ltd., GSK plc., Sanofi., Biological E Limited., Bharat Biotech., Bio Farma, Merck & Co., Inc., Valneva SE., Pfizer Inc., and KM Biologics among others.

Key Developments

• In June 2024, Sanofi announced a partnership with Biovac to start local manufacturing of inactivated polio vaccines (IPV) in Africa. This partnership enables polio vaccine supply to more than 40 African countries in the future and also supports the Africa CDC goal to have 60% of local vaccine production goal by 2040.
• In April 2024, the World Health Organization (WHO) provided prequalification for new oral inactivated cholera vaccine Euvichol-S. This prequalification adds the third product to the list of oral inactivated cholera vaccines produced by EuBiologicals Co.Ltd.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming pharmaceutical advancements.
• Type Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient Type delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global melanoma therapeutics market report would provide approximately 54 tables, 46 figures, and 195 pages.

Target Audience 2023

• Manufacturers: Pharmaceutical, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Pathogen
• 3.2. Snippet by Vaccine Type
• 3.3. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rising immunization programs across the globe
  • 4.1.2. Restraints
    • 4.1.2.1. Supply chain discrepancies
  • 4.1.3. Opportunities
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Epidemiology
• 5.3. Pricing Analysis
• 5.4. Pipeline Analysis
• 5.5. Patent Analysis
• 5.6. Regulatory Analysis

6. By Pathogen

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Pathogen
  • 6.1.2. Market Attractiveness Index, By Pathogen
• 6.2. Bacteria*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Virus

7. By Vaccine Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
  • 7.1.2. Market Attractiveness Index, By Vaccine Type
• 7.2. Polio Vaccine*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. DTaP Vaccine
• 7.4. Influenza Vaccine
• 7.5. Hepatitis Vaccine
• 7.6. Japanese Encephalitis Vaccine
• 7.7. Rabies Vaccine
• 7.8. Cholera Vaccine
• 7.9. Others

8. By Region

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 8.1.2. Market Attractiveness Index, By Region
• 8.2. North America
  • 8.2.1. Introduction
  • 8.2.2. Key Region-Specific Dynamics
  • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Pathogen
  • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
  • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.2.5.1. U.S.
    • 8.2.5.2. Canada
    • 8.2.5.3. Mexico
• 8.3. Europe
  • 8.3.1. Introduction
  • 8.3.2. Key Region-Specific Dynamics
  • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Pathogen
  • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
  • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.3.5.1. Germany
    • 8.3.5.2. U.K.
    • 8.3.5.3. France
    • 8.3.5.4. Spain
    • 8.3.5.5. Italy
    • 8.3.5.6. Rest of Europe
• 8.4. South America
  • 8.4.1. Introduction
  • 8.4.2. Key Region-Specific Dynamics
  • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Pathogen
  • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
  • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.4.5.1. Brazil
    • 8.4.5.2. Argentina
    • 8.4.5.3. Rest of South America
• 8.5. Asia-Pacific
  • 8.5.1. Introduction
  • 8.5.2. Key Region-Specific Dynamics
  • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Pathogen
  • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
  • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.5.5.1. China
    • 8.5.5.2. India
    • 8.5.5.3. Japan
    • 8.5.5.4. South Korea
    • 8.5.5.5. Rest of Asia-Pacific
• 8.6. Middle East and Africa
  • 8.6.1. Introduction
  • 8.6.2. Key Region-Specific Dynamics
  • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Pathogen
  • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type

9. Competitive Landscape

• 9.1. Competitive Scenario
• 9.2. Market Positioning/Share Analysis
• 9.3. Mergers and Acquisitions Analysis

10. Company Profiles

Key Market Players

• 10.1. Serum Institute of India Pvt. Ltd.*
  • 10.1.1. Company Overview
  • 10.1.2. Product Portfolio
    • 10.1.2.1. Product Description
    • 10.1.2.2. Product Key Performance Indicators (KPIs)
    • 10.1.2.3. Historic and Forecasted Product Sales
    • 10.1.2.4. Product Sales Volume
  • 10.1.3. Financial Overview
    • 10.1.3.1. Company Revenue's
    • 10.1.3.2. Geographical Revenue Shares
    • 10.1.3.3. Revenue Forecasts
  • 10.1.4. Key Developments
    • 10.1.4.1. Mergers & Acquisitions
    • 10.1.4.2. Key Product Development Activities
    • 10.1.4.3. Regulatory Approvals etc.
  • 10.1.5. SWOT Analysis
• 10.2. GSK plc.
• 10.3. Sanofi.
• 10.4. Biological E Limited.
• 10.5. Bharat Biotech.
• 10.6. Bio Farma
• 10.7. Merck & Co., Inc.
• 10.8. Valneva SE.
• 10.9. Pfizer Inc.
• 10.10. KM Biologics
• Similar data will be provided for each market player.

LIST NOT EXHAUSTIVE

11. Appendix

• 11.1. About Us and Services
• 11.2. Contact Us